Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | 0 | Antiviral activity against Reovirus | ChEMBL. | 17251029 |
Activity (functional) | 0 | Antiviral activity against RSV | ChEMBL. | 17251029 |
Activity (functional) | 0 | Antiviral activity against VSV | ChEMBL. | 17251029 |
CC50 (ADMET) | = 13 uM | Cytotoxicity against human MT4 cells after 96 hrs by MTT method | ChEMBL. | 17251029 |
CC50 (ADMET) | = 13 uM | Cytotoxicity against human MT4 cells after 96 hrs by MTT method | ChEMBL. | 17251029 |
CC50 (ADMET) | = 18 uM | Cytotoxicity against BHK1 cells after 48 to 120 hrs by MTT method | ChEMBL. | 17251029 |
CC50 (ADMET) | = 32 uM | Cytotoxicity against MDBK cells after 48 to 120 hrs by MTT method | ChEMBL. | 17251029 |
CC50 (ADMET) | = 50 uM | Cytotoxicity against Vero 76 cells after 48 to 120 hrs by MTT method | ChEMBL. | 17251029 |
EC50 (functional) | = 2 uM | Antiviral activity against CVB2 in Vero 76 cells after 3 days by plaque reduction assay | ChEMBL. | 17251029 |
EC50 (functional) | > 13 uM | Antiviral activity against HIV1 in MT4 cells by plaque reduction assay | ChEMBL. | 17251029 |
EC50 (functional) | > 18 uM | Antiviral activity against YFV in BHK1 cells assessed as inhibition of virus-induced cytopathogenicity after 2 to 3 days by MTT method | ChEMBL. | 17251029 |
EC50 (functional) | = 21 uM | Antiviral activity against | ChEMBL. | 17251029 |
EC50 (functional) | = 22 uM | Antiviral activity against BVDV in MDBK cells assessed as inhibition of virus-induced cytopathogenicity after 2 to 3 days by MTT method | ChEMBL. | 17251029 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.